Miroculus, a San Francisco startup developing microRNA-based diagnostic tests, said Monday that it has acquired Toronto-based microfluidics firm Kapplex for an undisclosed amount.
Miroculus emerged from stealth mode earlier this year at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference. It aims to tap into the growing evidence that miRNAs can serve as useful biomarkers for a number of conditions including cancer and infectious diseases.
As such, the company has culled the scientific literature to build an open database of miRNA associations with diseases and other biomolecules, and has also developed a prototype instrument platform to detect and analyze miRNA biomarkers from patient samples using isothermal amplification techniques.
Read the article at GenomeWeb